By Suherman Candra Maholtra 
The medical community is witnessing a potential paradigm shift in the prevention of nonmelanoma skin cancer following the release of a comprehensive study involving more than 33,000 veterans. Researchers have found that the early administration of nicotinamide, a specific form of vitamin B3, can significantly reduce the risk of developing subsequent skin cancers, particularly when initiated shortly after a patient’s first diagnosis. This large-scale analysis, conducted by experts at Vanderbilt University Medical Center and the Department of Veterans Affairs (VA), provides the most robust evidence to date supporting a preventative strategy that has been debated for nearly a decade.
For years, dermatologists have looked for cost-effective, low-risk interventions to stem the rising tide of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC). While sun protection and regular screenings remain the gold standard, the discovery that a simple vitamin supplement could bolster the body’s internal defenses has offered a new layer of hope. The latest findings suggest that the timing of this intervention is critical, potentially moving the clinical conversation from reactive treatment to proactive risk management.
The Evolution of Nicotinamide in Dermatological Practice
The journey of nicotinamide as a preventative agent in dermatology gained significant momentum in 2015. At that time, a landmark clinical trial known as the ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) study was published in the New England Journal of Medicine. This trial involved 386 participants who had a history of at least two nonmelanoma skin cancers within the previous five years. The results were striking: those who took 500 milligrams of nicotinamide twice daily saw a 23% reduction in new skin cancer diagnoses compared to the placebo group.
Despite these promising results, the 2015 study was relatively small in scope. In the years that followed, many dermatologists began recommending nicotinamide to high-risk patients, but the medical community lacked the large-scale data necessary to establish formal clinical guidelines. One of the primary challenges in gathering this data was the nature of the supplement itself. Because nicotinamide is available over the counter and is not a regulated prescription drug in many contexts, its use is rarely captured accurately in standard electronic medical records or insurance claims.
To bridge this data gap, researchers turned to the Veterans Affairs Corporate Data Warehouse. The VA system provided a unique advantage: nicotinamide is listed on its official formulary, meaning its prescription and use are meticulously documented across a massive and diverse patient population. This allowed the research team to conduct a retrospective analysis of a scale previously thought impossible.
Methodology: Mining the VA Corporate Data Warehouse
The research team, led by Lee Wheless, MD, PhD, an assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center, analyzed the records of 33,833 veterans. The study focused on patients who had received a baseline treatment of 500 milligrams of nicotinamide twice daily for a duration exceeding 30 days.
This cohort was compared against a control group of veterans who did not receive the supplement. The researchers tracked the clinical outcomes of these patients, specifically looking for subsequent diagnoses of basal cell carcinoma and cutaneous squamous cell carcinoma. By utilizing the VA’s integrated healthcare records, the team could account for various confounding factors, including age, gender, and pre-existing health conditions, providing a clearer picture of the supplement’s efficacy.
The study population was divided into two primary groups: 12,287 patients who had incorporated nicotinamide into their regimen and 21,479 who had not. This massive sample size allowed for a granular look at how different sub-populations responded to the treatment, including those who were immunocompromised.
Key Findings: The Critical Importance of Timing
The results of the study revealed an overall 14% decrease in the risk of developing new skin cancers among those who took nicotinamide. While this figure alone is statistically significant, the most compelling data emerged when the researchers analyzed the timing of the supplement’s introduction.
For patients who began taking nicotinamide immediately after their first skin cancer diagnosis, the reduction in risk was a staggering 54%. This suggests that there is a "window of opportunity" where the supplement is most effective at preventing the progression of skin cancer development. However, the study also found that this protective benefit diminished as the number of prior skin cancers increased. Patients who had already experienced multiple occurrences of BCC or SCC before starting the supplement saw a less pronounced reduction in risk.
Furthermore, the study highlighted that the protective effect was most robust against cutaneous squamous cell carcinoma. SCC is the second most common form of skin cancer and, while usually not life-threatening if caught early, it can be invasive and lead to significant disfigurement or metastasis if left untreated. The ability of nicotinamide to specifically target this type of cancer represents a major victory for preventative oncology.
Understanding the Biological Mechanism
The efficacy of nicotinamide lies in its ability to address the cellular damage caused by ultraviolet (UV) radiation. UV light from the sun or tanning beds damages the DNA in skin cells and depletes cellular energy (ATP). This energy depletion hampers the natural DNA repair mechanisms of the cell, leading to mutations that can eventually result in cancer.
Nicotinamide acts as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy production. By replenishing ATP levels, nicotinamide provides the skin cells with the "fuel" necessary to perform efficient DNA repair. Additionally, nicotinamide has been shown to reduce the immunosuppressive effects of UV radiation on the skin, further helping the body’s immune system identify and eliminate precancerous cells before they develop into tumors.
Importantly, nicotinamide is distinct from niacin (another form of vitamin B3). While niacin is known to cause "flushing"—a common and often uncomfortable side effect involving redness and itching of the skin—nicotinamide does not produce this reaction, making it a much more tolerable option for long-term daily use.
Implications for Immunocompromised Populations
The study also delved into a particularly vulnerable group: patients who are immunocompromised due to solid organ transplants. These individuals are at a significantly higher risk for skin cancer—sometimes hundreds of times higher than the general population—due to the immunosuppressive medications required to prevent organ rejection.
In this subgroup of 1,334 patients, the researchers found that the overall risk reduction was not statistically significant. However, a closer look at the data showed that early use of nicotinamide was still linked to a reduction in cases of cutaneous squamous cell carcinoma specifically. This suggests that while the supplement may not be a panacea for the most high-risk patients, it still holds value as part of a multi-faceted preventative strategy for transplant recipients.
Dr. Wheless noted that the findings in the immunocompromised group highlight the complexity of skin cancer prevention. The interplay between a suppressed immune system and the DNA-repairing properties of nicotinamide requires further investigation to determine the optimal dosage and timing for these specific patients.
Shifting Clinical Guidelines and Public Health Strategy
The implications of this study are far-reaching for the field of dermatology. Current practices often involve starting preventative treatments only after a patient has demonstrated a "high-frequency" of skin cancers. Dr. Wheless suggests that these findings should prompt a shift in that philosophy.
"There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population," Dr. Wheless stated. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier."
By intervening after the very first diagnosis, clinicians may be able to significantly alter the disease trajectory for millions of patients. This is particularly relevant given the economic burden of skin cancer. Nonmelanoma skin cancers are among the most frequently diagnosed cancers in the United States, and the costs associated with surgical excision, Mohs surgery, and follow-up care run into the billions of dollars annually. A low-cost, over-the-counter supplement that reduces the need for these procedures could result in substantial healthcare savings.
However, the researchers also emphasized the need for precision. "We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers," Wheless added. Identifying biomarkers or clinical profiles that predict which patients are likely to develop recurrent cancers will be the next frontier in refining nicotinamide therapy.
Research Collaboration and Future Outlook
The study was a collaborative effort involving several prominent researchers from Vanderbilt University, including Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas. The work was supported by a Department of Veterans Affairs grant (IK2CX002452), highlighting the government’s commitment to utilizing its vast data resources to improve veteran and public health.
As the medical community digests these findings, the focus will likely turn toward updating clinical protocols. Dermatologists may begin incorporating nicotinamide discussions into the initial post-operative visits of patients diagnosed with their first BCC or SCC. Furthermore, this study paves the way for future prospective trials that could examine the effects of different dosages or combinations of supplements.
While nicotinamide is not a substitute for traditional sun protection measures—such as wearing sunscreen, seeking shade, and wearing protective clothing—it represents a powerful secondary defense. As the population ages and cumulative UV exposure leads to higher rates of skin cancer, the integration of energy-boosting vitamins like nicotinamide into daily health regimens could become a cornerstone of dermatological wellness.
In conclusion, the VA study provides a definitive look at the potential of vitamin B3 to change the landscape of skin cancer prevention. By demonstrating that early intervention can cut the risk of subsequent cancers by more than half, researchers have provided a clear roadmap for improving patient outcomes and reducing the global burden of nonmelanoma skin cancer.
